Applying self-supervised AI to multi-modal electronic health records — integrating clinical notes, labs, and imaging — this project builds scalable diagnostic models to detect autoimmune diseases earlier and more precisely.
Building a fluorescence-based cellular screening platform to identify small molecules targeting mutant UBA1, this project addresses an acute unmet need in VEXAS syndrome and lays groundwork for broader rheumatic disease therapies.
Using single-molecule imaging to visualize B cell receptor signaling across gut compartments, this project uncovers how intestinal B cell education breaks down in IBD, revealing new targets for therapeutic intervention.
Identifying a novel molecular regulator of tolerogenic dendritic cell function, this project uncovers how its loss triggers spontaneous multiorgan autoimmunity and exacerbates lupus — revealing a clinically relevant pathway in immune tolerance.
A self-replicating RNA platform delivers anti-inflammatory cytokines directly to the airways, offering targeted local immune suppression without systemic toxicity — a mechanistically distinct approach to treating lupus lung disease.
Targeting the calcineurin-NFAT protein-protein interaction rather than enzyme active sites, this project develops a novel class of inhibitors to treat steroid-refractory ulcerative colitis with fewer side effects.
Identifying DNA methylation signatures in blood and urine as non-invasive biomarkers to classify lupus nephritis and guide treatment without repeated biopsies.
Engineering TET2-deficient beta cells that resist autoimmune attack to create replacement cell therapies for type 1 diabetes.
Developing an IFNγ-based molecular microscope to assess celiac disease activity and response to treatment without relying solely on diagnostic biopsies.
Using the RIP-NINJA mouse model to study how PD-1 regulation in the pancreas prevents autoimmune induction and checkpoint therapy-induced diabetes.
